Information Sharing by Healthcare Collaborations: Managing Antitrust Risk

Keeping you at the forefront of health care transformation and rebuilding means looking around the curve to what’s ahead.

Has your hospital or AMC considered using 3D printed devices in patient care? What are the regulatory considerations? Does the AMC become a manufacturer if it creates and uses a 3D printed device? What risks does the AMC taking on when manufacturing and using a 3D printed device. What contracts will be in place? Does the AMC need to purchase product liability insurance? This webinar will provide an overview of the regulatory, contractual and risk considerations when a provider manufactures and/or uses a 3D printed device.

Small cell lung cancer (SCLC) is aggressive and often difficult to treat, but many patients may have new hope. On August 17, 2018, the FDA approved the first immunotherapy the checkpoint inhibitor nivolumab (Opdivo, Bristol-Myers Squibb for patients with small cell lung cancer. Since this approval, there has been renewed focus on how to make different immunotherapies work for a disease which typicallly comprises 10-15% of all lung cancer cases. In this webinar for patients and caregivers, Matthew Hellmann, M.D., of Memorial Sloan Kettering Cancer Center discusses the new FDA approval, clinical trials, and potential treatments for patients with small cell lung cancer.

The healthcare ecosystem consists of those who pay, those who benefit and those who are responsible. New Care Models are helping to align these interests and share capacity across the ecosystem, all enabled by a modern digital infrastructure.This session will offer insights into how digital transformations are facilitating and improving the productivity of these New Care Models, including: Networked Care, Infrastructure-as-a-Service, Care-as-a-Service and Ambulatory Care.